MCL Literature Feed

Combining acalabrutinib with bendamustine-rituximab is safe and highly active, achieving a 78% complete response rate and unreached median progression-free survival at 47.6 months in treatment-naive mantle cell lymphoma.

In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.

In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.

This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.

For younger MCL patients post-transplant, this phase III analysis shows conditional survival improves over time, especially after R-CHOP, providing data for dynamic prognostication and reinforcing intensive induction.

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

This large Swedish real-world study on limited-stage MCL demonstrates that radiotherapy-containing frontline regimens are associated with excellent long-term outcomes, supporting a curative-intent, less-intensive approach for this rare subset.

This case report describes blastoid MCL presenting as an isolated cecal mass, highlighting an unusual clinical presentation and the need to consider lymphoma in the differential for GI tumors.

This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This case report demonstrates that MCL can cause severe renal failure via both direct infiltration and paraneoplastic glomerulonephritis, underscoring the need for kidney biopsy in unexplained nephropathy.

The polatuzumab-based regimen, Pola-R-mini-CHP, demonstrated efficacy in elderly relapsed/refractory MCL, offering a potential new ADC-chemoimmunotherapy option for this difficult-to-treat population.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

This review highlights that excellent outcomes with modern frontline chemo-immunotherapy plus BTK inhibitors are challenging the traditional role of autologous transplant consolidation in mantle cell lymphoma.

In a small retrospective study of nine untreated aggressive MCL patients, adding a BTKi to chemoimmunotherapy achieved a 100% objective response rate with manageable toxicity, suggesting a promising frontline strategy.

This retrospective study confirms poor outcomes for blastoid MCL with chemo-immunotherapy, advocating for upfront 2nd/3rd generation BTKi-based therapies to improve survival in this high-risk population.

This case of cardiac MCL with a mobile tumor highlights the risk of fatal pulmonary embolism post-chemotherapy, suggesting a potential role for pre-treatment surgical intervention in this rare presentation.

In older, frontline MCL patients, adding bortezomib to BR induction or lenalidomide to rituximab maintenance did not improve PFS, confirming BR-R as a highly effective standard.

Preclinically, dual inhibition of Hedgehog/GLI1 and Wnt/β-catenin pathways synergistically suppresses MCL cells and enhances sensitivity to chemotherapy and ibrutinib, suggesting a new approach to overcome resistance.

This first-reported case of sphenoid sinus MCL causing acute bilateral blindness demonstrates that prompt chemo-surgical intervention can partially reverse vision loss, highlighting a rare but critical CNS presentation.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.

This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.